<DOC>
	<DOCNO>NCT01123265</DOCNO>
	<brief_summary>The purpose study determine whether DC-STAMP , protein surface osteoclast precursor ( OCPs ) , use biologic marker Psoriatic Arthritis ( PsA ) . With marker investigator hope learn OCPs develop well find DC-STAMP predicts PsA severity well treatment work PsA .</brief_summary>
	<brief_title>National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein ( DC-Stamp ) Biomarker Study</brief_title>
	<detailed_description>Psoriatic Arthritis ( PsA ) , phenotypically heterogeneous disorder , characterize joint damage observe half patient early disease . While anti-tumor necrosis factor ( TNF ) agent greatly improve sign symptom lessen joint damage , fact fraction patient achieve complete remission underscore tremendous unmet need population . To date , biomarker stratify patient severity serve lead indicator treatment response identify . Our laboratory demonstrate circulate osteoclast precursor ( OCP ) elevate PsA patient . OCP decline rapidly follow anti-TNF therapy level higher subject erosive arthritis compare x-ray change . The OCP derive CD14+ monocyte assay entails culture technique costly , expensive labor intensive . We develop antibody ( 1A2 ) Dendritic Cell Specific Transmembrane Protein ( DC-STAMP ) , potential marker OCP population , analysis flow cytometry . We find : 1 ) level monocyte DC-STAMP expression correlate vitro osteoclast formation ; 2 ) DC-STAMP expression significantly elevate PBMC PsA subject compare control ; 3 ) TNF dramatically upregulated expression DC-STAMP vitro ; 4 ) DC-STAMP surface expression decline follow anti-TNF therapy ; 5 ) subset CD3+ cell also express DC-STAMP cell membrane . Based preliminary data , three hypothesis propose : 1 . DC-STAMP+ CD3+ T cell belong Th17 subset facilitates OC generation ; 2 . DC-STAMP marker disease severity PsA ; 3 . DC-STAMP biomarker treatment response PsA . We propose three Specific Aims test hypothesis . Aim 1 To examine whether DC-STAMP+CD3+ cell belong Th17 cell subset , PBMC stain Th17-specific antibody PsA subject elevate DC-STAMP expression . We also examine role T cell osteoclastogenesis directly co-culture experiment use monocyte culture without added lymphocyte control . The expression DC-STAMP circulating dendritic cell examine ex vivo 11-color flow cytometry . Aim 2 To determine increase DC-STAMP expression associate severe feature PsA , DC-STAMP expression 40 PsA subject determine correlated clinical variable arthritis skin disease , CRP x-ray damage . Aim 3 To examine DC-STAMP response marker anti-TNF treatment , recruit 20 PsA patient Aim 2 elevate DC-STAMP expression divide 2 group . Ten subject receive methotrexate , ten receive anti-TNF therapy . The correlation DC-STAMP variable ( percentage 1A2+ divide 1A2 - cell X 100 ) variable detail Aim 2 analyze 2 treatment group 2 different time point .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . Subject must &gt; 18 year old 2 . Subject must &gt; 3 tender swollen joint 3 . Subject must must target lesion great 3 cm diameter 4 . Subjects meet ClASsification Psoriatic ARthritis ( CASPAR ) criteria PsA 5 . Subjects must DCSTAMP pattern III IV 1 . Subjects active inflammatory synovitis , dactylitis , enthesitis , osteoarthritis , axial disease , Subjects SLE , Sjogren 's syndrome , scleroderma inflammatory muscle disease 2 . Subjects active malignancy 3 . Subjects currently biologic agent ( antiTNF agent , antiT B cell agent ) and/or diseasemodifying antirheumatic drug ( DMARDs ) ( methotrexate , leflunomide , hydroxychloroquine , azulfidine , cyclosporine , azathioprine ) 4 . Subjects DMARDs biologics less 3 month 5 . Subjects judge ineligible discretion PI 6 . Subjects history crystalline arthritis ( gout , pseudogout ) 7 . Subject pregnancy breast feed 8 . History recurrent infection AIM 3 Specific 9 . Demyelinating disorder AIM 3 Specific 10 . Prior nonresponsiveness TNFi AIM 3 Specific 11 . Subjects BMI &gt; 30 AIM 3 Specific MTX arm 12 . Subjects history type II diabetes AIM 3 Specific MTX arm 13 . Subjects history substance abuse include alcohol AIM 3 Specific MTX arm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>PsA</keyword>
	<keyword>methotrexate</keyword>
	<keyword>Anti-TNF</keyword>
	<keyword>TNF</keyword>
	<keyword>DC-Stamp</keyword>
</DOC>